Nature CommunicationsBioengineeringPeer-reviewed journal article
Human cell surface-AAV interactomes identify LRP6 as blood-brain-barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder
T. F. Shay, S. Jang, X. Chen, B. Walker, C. Tebbutt, D. A. Wolfe, T. J. Brittain, C. M. Arokiaraj, E. E. Sullivan, X. Ding, T.-Y. Wang, Y. Lei, M. R. Chuapoco, T.-F. Chou, V. Gradinaru
Abstract
Adeno-associated viruses (AAVs) are foundational gene delivery tools for basic science and clinical therapeutics. However, lack of mechanistic insight, especially for engineered vectors created by directed evolution, can hamper their application. Here, we adapted an unbiased human cell microarray platform to determine the extracellular and cell surface interactomes of natural and engineered AAVs. We identified a naturally-evolved and serotype-specific interaction between the AAV9 capsid and human interleukin 3 (IL3), with possible roles in host immune modulation, as well as lab-evolved low-density-lipoprotein-receptor-related-protein 6 (LRP6) interactions specific to engineered capsids that cross the blood-brain barrier in non-human primates after intravenous administration. The unbiased cell microarray screening approach also allowed us to identify off-target tissue binding interactions of engineered brain-enriched AAV capsids that may inform vectors peripheral organ tropism and side effects. These results allow confident application of engineered AAVs in diverse organisms and unlock future target-informed engineering of improved viral and non-viral vectors for non-invasive therapeutic delivery to the brain.
- organism: human
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting AAV vectors to the CNS via de novo engineered capsid-receptor interactions
Qin Huang, Albert Tian Chen, … Benjamin E. Deverman·bioRxiv·Oct 31, 2022
- Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids
Qin Huang, Ken Y. Chan, … Benjamin E. Deverman·PLoS ONEPeer-reviewed·Nov 14, 2019
- LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates
Zhenhua Wang, Xianggang Xu, … Zhenming An·bioRxiv·Mar 18, 2026
- Highly conserved brain vascular receptor ALPL mediates transport of engineered viral vectors across the blood-brain barrier
Tyler Chistopher Moyer, Brett A. Hoffman, … Mathieu E. Nonnenmacher·bioRxiv·Mar 12, 2024
- Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids
Tyler J. Brittain, Seongmin Jang, … Viviana Gradinaru·Molecular TherapyPeer-reviewed·Mar 28, 2026
- New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets
S. G. Giannelli, M. Luoni, … V. Broccoli·bioRxiv·Jun 27, 2023